98%
921
2 minutes
20
A potent, in vivo efficacious 11β hydroxysteroid dehydrogenase type 1 (11β HSD1) inhibitor (11j) has been identified. Compound 11j inhibited 11β HSD1 activity in human adipocytes with an IC of 4.3nM and in primary human adipose tissue with an IC of 53nM. Oral administration of 11j to cynomolgus monkey inhibited 11β HSD1 activity in adipose tissue. Compound 11j exhibited >1000× selectivity over other hydroxysteroid dehydrogenases, displays desirable pharmacodynamic properties and entered human clinical trials in 2011.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmc.2017.04.033 | DOI Listing |
Proteomics Clin Appl
August 2025
Institute of Next Generation Material Design, Hanyang University, Seoul, Republic of Korea.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one-fourth of the global population, yet effective diagnostics and treatments remain limited. Systemic immune dysregulation plays a key role in MASLD pathogenesis, highlighting the value of immune profiling.
Methods: In this study, we used high-dimensional single-cell mass cytometry (CyTOF) to analyze peripheral blood mononuclear cells (PBMCs) from healthy donors (n = 6), MASLD patients (n = 4), and MASLD patients treated with an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor (n = 2).
Chem Biol Interact
August 2025
Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China; Key Laboratory of Pediatric Anesthesiology, Ministry of Education, Wenzhou Medical University, Wenzhou, 325027, Zhej
Mycotoxins are secondary metabolites produced by fungi and pose significant risks to human and animal health. This study aimed to determine inhibitory potency of 7 mycotoxins and metabolites (cyclopiazonic acid, deoxynivalenol, patulin, zearalenone, α-zearalenol, β-zearalenol, and β-zearalanol) against human placental 3β-hydroxysteroid dehydrogenase 1 (h3β-HSD1) and rat homolog r3β-HSD4, as well as their effects on progesterone output in human JAr cells and perform mechanism and structure-activity relationship analysis. In placentas, h3β-HSD1 is responsible for pregnenolone-to-progesterone conversion.
View Article and Find Full Text PDFJ Comput Aided Mol Des
August 2025
Department of Toxicology and Bromatology, Faculty of Pharmacy, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, A. Jurasza 2 Street, 85089, Bydgoszcz, Poland.
This research aims to develop a predictive model to support the design of new 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors based on the pseudothiohydantoin scaffold, offering potential for novel treatments of metabolic disorders. The Quantitative Structure-Activity Relationship (QSAR) analysis was performed on 56 2-aminothiazol-4(5h)-one derivatives, for which the 11β-HSD1 inhibitory activity was previously reported. Gaussian software was employed for geometry optimization, while Dragon software was used to calculate the molecular descriptors.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Department of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University ERICA, Ansan 15588, Gyeonggi-do, Republic of Korea.
Skeletal muscle atrophy is a critical health issue affecting the quality of life of elderly individuals and patients with chronic diseases. These conditions induce dysregulation of glucocorticoid (GC) secretion. GCs play a critical role in maintaining homeostasis in the stress response and glucose metabolism.
View Article and Find Full Text PDFInt J Mol Sci
July 2025
Brazilian Society of Obesity Medicine, Florianópolis 88070-800, Brazil.
Lipedema is a chronic, estrogen-sensitive adipose tissue disorder characterized by disproportionate subcutaneous fat accumulation, fibrosis, inflammation, and resistance to fat mobilization. Despite its high prevalence, lipedema remains poorly understood and frequently misdiagnosed. This narrative review proposes a novel pathophysiological model in which menopause acts as a critical turning point in the progression of lipedema, driven by estrogen receptor imbalance (ERβ predominance over ERα), intracrine estrogen excess, and adipose tissue dysfunction.
View Article and Find Full Text PDF